Abstract：Aim Expressing the capsid protein (p24) of human immunodeficiency virus type 1 (HIV-1 ) for preparing monoclonal antibody against HIV. Methods The p24 gene fragment encoding the p24 protein was recombined and inserted into expression vector PET─ 17b under the control of the bacteriophage T7 promoter. The recombinant vector was transferred into Escherchia coli (E. coli) BL21 (DE3), and induced by IPTG.The expressed protein was analyzed by SDS-PAGE, Western blotting, and immunodot blotting. Results A recombiant plasmid pET24 expressing the p24 protein of HIV─ 1 was successfully constructed. Induced by IPTG,the pET24 plasmid highly expressed a 30kDa protein of s10-p24 spanning 284 amino acid residues. The total amount of the fusion protein was approximately 38. 4% of the celluar protein in E. coli. Western blotting and immunodot blotting indicated that the recombinant protein could be recognized by anti-p24 monoclonal antibody and HIV-1 positive sera respectively. Conclusions The recombinant protein is useful for preparing specific antibody and diagnostic usage.
1.Dorfman T, et al. Functional domains of the capsid proteinof human immunodeficiency virus type I.J Virol, 1994,68:818.
2. Gelderblom HR,et al. Fiue structure of human immunode-ficuncy virus(HIV)and immunolocalzation of structuralproteins.Virology,1987,156:171.
3. Mervis RJ, et al. The gag gene products of human immun-odeficiehey virus type Ialignment with in the gag geneopen reading frame identification of postransiational modi-fications and evidence for alternative gag precursos.J Vi-rol, 1988, 62: 3993.
4.Dani PB. HIV antibodies and vaccine design. AIDS, 1989,3(Suppll): s111.
5. Buseyne F, et al. Gag-specific cytotoxic T lymphocytesfrom human immunodeficiency virus type I-infected indi-viduals Gag epitopes are clustered in three regions of thep24gag protein.J Virol, 1993, 67: 694.
6.Nara PL, et al. Nutralization of HIV - I: a parodox ofhumaoral proporitos. FASEB J , 1991, 5: 2437.
7.Rood AH,et al.Sera from HTLV -Ⅲ/LAV antibody positive individuals mediate antibody—dependent cellular cyto-toxlclty against HTI.V—Ⅲ/LAV-infected T cells.JIm-munol,1987,138:1064.
8.Joller-Jemelka HI,et al.Anti-HIV IgM antibody analysisduring early manifestations of HIV infection. AIDS, 1987,1:45.
9.Lange JMA.et al.Persistent HIV antigenaemia and declineof HIV core antibodies associated with transition AIDS.BrMed J, 1986, 293: 1459.
10. Chargelegue D, etal. A 7—year analysis of anti-Gag(P17 and p24)antibodies in HIV-1-seropositive patientwith haemophilin: immunoglobulin G titre and activityate eady predictors of clinical course.AIDS,1993,7(Suppl 2):587.
11.Rossmann MG.Antiviral agents targeted to interact withvlral capsid proteins and a possible application to humanimmunodeflclency virus. Proc Nail Acad Set U S A,1988,85:4625.
12.Tanaka N, et al. A slmplemethod for overproductlon andpurification of p24 Gag protein of human immunodefi-ciency virus typeI.Microbiol Immunol,1992,36(8):823.
13. Hausdorf G, et al. A recombinant human immunodefi-clency virus type-1capsid protein(rp24)its expression,purification and physico-chemicalcharacterization.J Vi-rol Method,1994,50:(1一3):1.
14.吴卫星等.在大肠杆菌中高效表达I型人类免疫缺陷病毒(HIV— I)核心蛋白,中华微生物学和免疫学杂志,1992, 12(11):5.
15. Sambrook J, Fritsch EF. Maniatis T.著.金冬雁,黎孟枫译.分子克隆实验指南.第二版,北京:科学出版社.1992:16～68.
16. Studier FW, et al.Use of bacteriophage T7 RNA poly-merase to direct selective high-level expression of clonedgenes.J Mol Biol, 189: 113
